Latest Immuno Oncology News

Immutep Limited’s Phase II EFTISARC-NEO trial reveals a novel immunotherapy combo delivering a striking 51.5% tumour response in soft tissue sarcoma patients, alongside robust immune activation signals.

Noxopharm Limited has been granted its first US patent for the Sofra™ technology platform, marking a key milestone in its cancer immunotherapy research. This patent protects the company’s innovative immune-modulatory oligonucleotides, underpinning its expanding pipeline in a rapidly growing market.

Immutep Limited reported a widened loss of A$61.4 million for FY2025, driven by increased R&D and clinical trial expenses, while progressing its lead immunotherapy candidate into a pivotal Phase III lung cancer trial. The company maintains a robust cash position supporting operations through 2026.

Imugene Limited has successfully closed its Share Purchase Plan, raising $2.42 million following a $22.5 million institutional placement, reinforcing its capital position for ongoing immuno-oncology development.

Percheron Therapeutics posted a 25% increase in net loss for FY2025 amid termination of its Duchenne Muscular Dystrophy programs. The company pivots strategically to oncology with the in-licensing of HMBD-002, a monoclonal antibody targeting VISTA, aiming to initiate Phase II trials in 2026.

Imugene Limited reported a significant 54% reduction in net loss for FY25, driven by cost efficiencies and promising clinical progress in its immuno-oncology pipeline. The company’s lead asset, azer-cel, achieved a 79% response rate in Phase 1b trials and secured FDA Fast Track designation.

Noxopharm’s Sofra™ technology shows promising results in collaboration with US biotech Tezcat Biosciences, advancing targeted drug delivery for cancer and inflammatory diseases.

Imugene Limited reports strong clinical progress with its off-the-shelf CAR T therapy azer-cel achieving a 75% overall response rate in Phase 1b trials, alongside new patents and leadership appointments. The company also secured $22.5 million in fresh funding to advance pivotal trials.

Percheron Therapeutics has licensed HMBD-002, a promising immuno-oncology candidate, completed FDA IND transfer, and plans to launch phase II trials in 2026. The company also reported a solid cash position and issued loyalty options to shareholders.

Imugene Limited has launched a $37.5 million equity raising through a Placement and Share Purchase Plan, offering new shares and options to fund its pivotal azer-cel clinical program. The raise includes attaching and piggyback options, subject to shareholder approval, aiming to bolster the company’s immuno-oncology pipeline.

Imugene Limited has launched a A$37.5 million capital raising to advance its promising off-the-shelf CAR T therapy, azer-cel, following encouraging Phase 1b data showing a 75% overall response rate in lymphoma patients.

Imugene Limited has completed a $22.5 million institutional placement and launched a $15 million Share Purchase Plan, both featuring attaching options, to fund its azer-cel clinical program through a pivotal trial in 2026.